CA2864026C - Diagnostic de la sclerose en plaques - Google Patents

Diagnostic de la sclerose en plaques Download PDF

Info

Publication number
CA2864026C
CA2864026C CA2864026A CA2864026A CA2864026C CA 2864026 C CA2864026 C CA 2864026C CA 2864026 A CA2864026 A CA 2864026A CA 2864026 A CA2864026 A CA 2864026A CA 2864026 C CA2864026 C CA 2864026C
Authority
CA
Canada
Prior art keywords
metabolites
blood
glucose
concentration
phosphocholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2864026A
Other languages
English (en)
Other versions
CA2864026A1 (fr
Inventor
Daniel Anthony
Nicola Sibson
Jacqueline PALACE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of CA2864026A1 publication Critical patent/CA2864026A1/fr
Application granted granted Critical
Publication of CA2864026C publication Critical patent/CA2864026C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé in vitro de diagnostic de la sclérose en plaque chez un sujet humain, consistant à (i) déterminer les concentrations d'au moins deux métabolites dans un échantillon dudit sujet, les deux métabolites ou plus étant choisis parmi : des métabolites sanguins, lesdits métabolites sanguins comprenant : l'alanine, l'acide ascorbique, la choline, un acide gras, le glucose, le lactate, la N-acétyl aspartate, la N-acétyl glycoprotéine, le n-butyrate, l'acide oxyglutarique, la phosphocholine, la taurine bétaïne, la tyrosine, la L-glutamine, les espèces de N-acétyl et le bêta-hydroxybutyrate; et/ou des métabolites urinaires, lesdits métabolites urinaires comprenant : le citrate, la créatinine, l'inositol, le lactate et le N-oxyde de triméthylamine (TMAO); (ii) comparer les concentrations desdits deux métabolites ou plus dans l'échantillon avec les concentrations des mêmes métabolites dans au moins un étalon de référence; et (iii) identifier une différence de concentration pour chacun desdits deux métabolites ou plus dans l'échantillon par rapport à l'étalon de référence; lesdites différences de concentration correspondant à la présence d'une sclérose en plaques.
CA2864026A 2012-02-07 2013-02-07 Diagnostic de la sclerose en plaques Active CA2864026C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1202092.1 2012-02-07
GBGB1202092.1A GB201202092D0 (en) 2012-02-07 2012-02-07 Diagnosing multiple sclerosis
PCT/GB2013/050285 WO2013117930A2 (fr) 2012-02-07 2013-02-07 Diagnostic de la sclérose en plaques

Publications (2)

Publication Number Publication Date
CA2864026A1 CA2864026A1 (fr) 2013-08-15
CA2864026C true CA2864026C (fr) 2023-08-22

Family

ID=45896738

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864026A Active CA2864026C (fr) 2012-02-07 2013-02-07 Diagnostic de la sclerose en plaques

Country Status (7)

Country Link
US (2) US20150338389A1 (fr)
EP (1) EP2812690B1 (fr)
AU (1) AU2013217415B2 (fr)
CA (1) CA2864026C (fr)
ES (1) ES2642186T3 (fr)
GB (1) GB201202092D0 (fr)
WO (1) WO2013117930A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201509658D0 (en) 2015-06-03 2015-07-15 Isis Innovation Method of diagnosis
KR101983447B1 (ko) * 2017-07-05 2019-05-28 가천대학교 산학협력단 다발성 경화증 및 시신경 척수염 범주 질환을 구별하는 방법
GB202202989D0 (en) * 2022-03-03 2022-04-20 Univ Oxford Innovation Ltd Methods for monitoring multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101479230A (zh) * 2006-05-26 2009-07-08 菲诺梅诺米发现公司 用于诊断多发性硬化的生物标记及其方法
WO2008033575A2 (fr) * 2006-09-15 2008-03-20 Metabolon, Inc. Procédés d'identification de cheminements biochimiques
CA2721129A1 (fr) * 2007-04-12 2008-10-23 Carolyn Marie Slupsky Detection urinaire d'un etat pathologique provoque par une infection a pneumocoque
WO2011041892A1 (fr) * 2009-10-09 2011-04-14 Carolyn Slupsky Procédés pour le diagnostic, le traitement et la surveillance de la santé d'un patient en utilisant la métabolomique
JP2013512444A (ja) * 2009-12-01 2013-04-11 メタノミクス ヘルス ゲーエムベーハー 多発性硬化症を診断するための手段及び方法

Also Published As

Publication number Publication date
WO2013117930A3 (fr) 2013-11-14
US20150338389A1 (en) 2015-11-26
GB201202092D0 (en) 2012-03-21
AU2013217415A1 (en) 2014-09-25
CA2864026A1 (fr) 2013-08-15
EP2812690B1 (fr) 2017-07-26
ES2642186T3 (es) 2017-11-15
WO2013117930A2 (fr) 2013-08-15
US20180372716A1 (en) 2018-12-27
EP2812690A2 (fr) 2014-12-17
AU2013217415B2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
EP1171778B1 (fr) Methode utilisant l'irm pour determiner le risque de developper un diabete non insulino-dependant
Bodaghi et al. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases
Mattsson et al. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Barba et al. Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy‐based metabolomics
Hassan-Smith et al. The role of metabolomics in neurological disease
US9823204B2 (en) Metabolomics-based biomarkers for lung function
CN102933966A (zh) 阿尔茨海默病的新型诊断制剂
US9500660B2 (en) Isovalerylglycine as biomarker for the predispositon for weight gain and obesity
AU2013354356B2 (en) Trimethylamine-N-oxide as biomarker for the predisposition for weight gain and obesity
US20180372716A1 (en) Diagnosing multiple sclerosis
Culeddu et al. NMR-based metabolomic study of type 1 diabetes
Barba et al. Metabolomics and heart diseases: from basic to clinical approach
JP2019168319A (ja) 小児がん検査用尿中代謝物マーカー
Yao et al. Serum metabolomics profiling to identify biomarkers for unstable angina
CN104350384B (zh) Pc‑o 44:4－一种用于内脏脂肪过多的生物标志物
A't Hart et al. Non-invasive measurement of brain damage in a primate model of multiple sclerosis
JP7226732B2 (ja) 尿中腫瘍マーカーによるがん検出方法、キット及び装置
Yoon et al. Altered cell viability and proliferation activity of peripheral lymphocytes in patients with Alzheimer's disease
Kim et al. Metabolite Markers for Characterizing Sasang Constitution Type through GC‐MS and 1H NMR‐Based Metabolomics Study
Botello-Marabotto et al. Non-invasive biomarkers for mild cognitive impairment and Alzheimer's disease
US20060210476A1 (en) Metabonomics homogeneity analysis
Vignoli et al. NMR-based metabolomics in Alzheimer’s disease research: a review
US20210278405A1 (en) Identification of metabolomic signatures in urine samples for tuberculosis diagnosis
Puranik et al. Insight into Early Diagnosis of Multiple Sclerosis by Targeting Prognostic Biomarkers
Zeng et al. Correlation between abnormal cellular immune and changes of magnetic resonance spectroscopy in patients with Alzheimer’s disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180206

EEER Examination request

Effective date: 20180206

EEER Examination request

Effective date: 20180206

EEER Examination request

Effective date: 20180206

EEER Examination request

Effective date: 20180206

EEER Examination request

Effective date: 20180206

EEER Examination request

Effective date: 20180206